Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Klinger

Showing results (251-260 of 274) with videos related to

Pageof 28
Sort By:
American Journal of Respiratory Cell and Molecular Biology|November 14, 2019
Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in RatsJames R Klinger, Mandy Pereira, Michael Del Tatto, et al.
Cardiovascular Research|January 12, 2022
Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertensionEuy-Myoung Jeong, Mandy Pereira, Eui-Young So, et al.
Pulmonary Circulation|August 18, 2025
Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE StudiesJames R Klinger, Hikmet Al-Hiti, Sung-A Chang, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
Annals of the American Thoracic Society|September 5, 2020
Insights from the Menstrual Cycle in Pulmonary Arterial HypertensionGrayson L Baird, Thomas Walsh, Jason Aliotta, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Impaired SOX17 Expression Causes Endothelial Dysfunction and Pulmonary Arterial Hypertension by Insufficient Suppression of RUNX1Bedia Akosman, Moon Jung Choi, Yamini Sharma, et al.
Circulation|April 17, 2023
<i>SOX17</i> Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary HypertensionRachel Walters, Eleni Vasilaki, Jurjan Aman, et al.
Annals of the American Thoracic Society|March 3, 2022
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association RegistryRoberto J Bernardo, Di Lu, Ramon L Ramirez, et al.
Scientific Reports|December 18, 2023
Transcriptional profiles of pulmonary artery endothelial cells in pulmonary hypertensionNavneet Singh, Carsten Eickhoff, Augusto Garcia-Agundez, et al.
American Journal of Respiratory and Critical Care Medicine|September 8, 2016
Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled TrialSteven M Kawut, Christine L Archer-Chicko, Angela DeMichele, et al.
Pageof 28

Showing results (251-260 of 274) with videos related to

Sort By:
Pageof 28
American Journal of Respiratory Cell and Molecular Biology|November 14, 2019
Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in RatsJames R Klinger, Mandy Pereira, Michael Del Tatto, et al.
Cardiovascular Research|January 12, 2022
Targeting RUNX1 as a novel treatment modality for pulmonary arterial hypertensionEuy-Myoung Jeong, Mandy Pereira, Eui-Young So, et al.
Pulmonary Circulation|August 18, 2025
Predicting Response to Switching From Phosphodiesterase Type 5 Inhibitor to Riociguat in Patients With Pulmonary Arterial Hypertension: Biomarker and Responder Analysis of the RESPITE and REPLACE StudiesJames R Klinger, Hikmet Al-Hiti, Sung-A Chang, et al.
The European Respiratory Journal|September 11, 2017
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitorsMarius M Hoeper, Gérald Simonneau, Paul A Corris, et al.
Annals of the American Thoracic Society|September 5, 2020
Insights from the Menstrual Cycle in Pulmonary Arterial HypertensionGrayson L Baird, Thomas Walsh, Jason Aliotta, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Impaired SOX17 Expression Causes Endothelial Dysfunction and Pulmonary Arterial Hypertension by Insufficient Suppression of RUNX1Bedia Akosman, Moon Jung Choi, Yamini Sharma, et al.
Circulation|April 17, 2023
<i>SOX17</i> Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary HypertensionRachel Walters, Eleni Vasilaki, Jurjan Aman, et al.
Annals of the American Thoracic Society|March 3, 2022
Hispanic Ethnicity and Social Determinants of Health in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association RegistryRoberto J Bernardo, Di Lu, Ramon L Ramirez, et al.
Scientific Reports|December 18, 2023
Transcriptional profiles of pulmonary artery endothelial cells in pulmonary hypertensionNavneet Singh, Carsten Eickhoff, Augusto Garcia-Agundez, et al.
American Journal of Respiratory and Critical Care Medicine|September 8, 2016
Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled TrialSteven M Kawut, Christine L Archer-Chicko, Angela DeMichele, et al.
Pageof 28